Immuneering Corp
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $0.0 | $0.3 | $2.1 |
| Operating income | -$59.4 | -$64.1 | -$58.4 | -$51.7 | -$33.9 |
| Net income | -$56.0 | -$61.0 | -$53.5 | -$50.5 | -$33.5 |
| Cash Flow Statement | |||||
| Free cash flow | -$45.5 | -$55.1 | -$49.3 | -$44.8 | -$30.9 |
Shares outstanding 64.7M · Free float 79.7%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.